CTMX · Cytomx Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.26M | - | $5.96M | $18.66M | $50.92M | - | $33.43M | $25.11M | $41.46M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $19.24M | - | $15.30M | $13.32M | $18.87M | - | $21.37M | $25.17M | $22.05M | - |
| SG&A | $10.69M | - | $6.43M | $6.62M | $9.43M | - | $7.95M | $8.39M | $7.75M | - |
| Total Operating Expenses | $29.93M | - | $21.73M | $19.94M | $28.30M | - | $29.32M | $33.57M | $29.81M | - |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | ($19.67M) | - | ($15.77M) | ($1.29M) | $22.62M | - | $4.11M | ($8.45M) | $11.66M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $59.0K | - | $58.0K | $63.0K | $62.0K | - | $61.0K | $0 | $49.0K | - |
| Net Income | ($18.25M) | - | ($14.23M) | ($154.0K) | $23.52M | - | $5.74M | ($6.53M) | $13.79M | - |
| EPS - Basic | - | - | - | - | - | - | - | - | - | - |
| EPS - Diluted | - | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $28.83M | $12.67M | $34.19M | $49.04M | $47.60M | $38.05M | $40.58M | $43.25M | $36.19M | $17.17M |
| Accounts Receivable | $646.0K | $2.01M | $1.63M | $1.87M | $1.96M | $3.10M | $3.35M | $2.77M | $13.18M | $3.43M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.37M | $1.30M | $646.0K | $227.0K | $276.0K | $1.09M | $1.42M | $611.0K | $1.96M | $1.46M |
| Current Assets | $353.10M | $143.92M | $149.22M | $164.62M | $86.63M | $107.31M | $124.18M | $143.08M | $167.25M | $182.94M |
| Total Assets | $359.36M | $151.57M | $158.25M | $175.06M | $98.50M | $120.53M | $138.98M | $159.22M | $184.69M | $201.79M |
| Current Liabilities | $34.02M | $46.62M | $41.03M | $39.22M | $50.20M | $85.77M | $119.23M | $142.86M | $144.54M | $155.91M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $39.41M | $52.56M | $50.87M | $55.15M | $73.45M | $120.99M | $162.43M | $190.45M | $216.37M | $249.24M |
| Stockholders' Equity | $319.94M | $99.01M | $107.39M | $119.91M | $25.05M | ($456.0K) | ($23.45M) | ($31.23M) | ($31.68M) | ($47.45M) |
| Retained Earnings | ($730.20M) | ($711.95M) | ($682.44M) | ($668.21M) | ($668.05M) | ($691.58M) | ($710.46M) | ($716.19M) | ($709.66M) | ($723.45M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($25.55M) | - | - | - | ($21.04M) | - | - | - | ($26.05M) | - |
| Investing Cash Flow | ($192.78M) | - | - | - | $30.60M | - | - | - | $44.88M | - |
| Financing Cash Flow | $234.49M | - | - | - | $0 | - | - | - | $174.0K | - |
| CapEx | $0 | - | - | - | $119.0K | - | - | - | $115.0K | - |
| Free Cash Flow | ($25.55M) | - | - | - | ($21.16M) | - | - | - | ($26.16M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -191.8% | - | -264.4% | -6.9% | 44.4% | - | 12.3% | -33.7% | 28.1% | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | -177.9% | - | -238.6% | -0.8% | 46.2% | - | 17.2% | -26.0% | 33.3% | - |
| Free cash flow margin | -249.1% | - | - | - | -41.6% | - | - | - | -63.1% | - |
| FCF / Net income | 1.40 | - | - | - | -0.90 | - | - | - | -1.90 | - |
| R&D / Revenue | 187.5% | - | 256.6% | 71.4% | 37.1% | - | 63.9% | 100.2% | 53.2% | - |
| SG&A / Revenue | 104.2% | - | 107.8% | 35.5% | 18.5% | - | 23.8% | 33.4% | 18.7% | - |
| Effective tax rate | - | - | - | - | 0.3% | - | 1.1% | - | 0.4% | - |
| Return on assets | -5.1% | - | -9.0% | -0.1% | 23.9% | - | 4.1% | -4.1% | 7.5% | - |
| Return on equity | -5.7% | - | -13.2% | -0.1% | 93.9% | - | -24.5% | 20.9% | -43.5% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 10.38 | 3.09 | 3.64 | 4.20 | 1.73 | 1.25 | 1.04 | 1.00 | 1.16 | 1.17 |
| Quick ratio | 10.38 | 3.09 | 3.64 | 4.20 | 1.73 | 1.25 | 1.04 | 1.00 | 1.16 | 1.17 |
| Cash ratio | 0.85 | 0.27 | 0.83 | 1.25 | 0.95 | 0.44 | 0.34 | 0.30 | 0.25 | 0.11 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.12 | 1.53 | 1.47 | 1.46 | 3.93 | -264.33 | -5.93 | -5.10 | -5.83 | -4.25 |
| Liabilities / Assets | 0.11 | 0.35 | 0.32 | 0.32 | 0.75 | 1.00 | 1.17 | 1.20 | 1.17 | 1.24 |
| Efficiency | ||||||||||
| Asset turnover | 0.03 | - | 0.04 | 0.11 | 0.52 | - | 0.24 | 0.16 | 0.22 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 23d | - | 100d | 37d | 14d | - | 37d | 40d | 116d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 2.6x | - | 4.9x | 2.4x | 2.2x | - | - | - | - | - |
| P / S | 81.2x | - | 88.3x | 15.7x | 1.1x | - | 3.0x | 4.1x | 4.3x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -79.9% | - | -82.2% | -25.7% | 22.8% | - | 26.7% | 1.6% | 76.4% | - |
| Revenue CAGR (3y) | -24.1% | - | -29.4% | 0.9% | 43.8% | - | 23.9% | 15.5% | 37.4% | - |
| Revenue CAGR (5y) | -8.5% | - | -19.6% | 2.4% | 0.5% | - | 25.6% | 22.7% | 7.1% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | - | 84.8% | 94.1% | - | 31.6% | -152.4% | - | - |
| Net income growth (YoY) | - | - | - | 97.6% | 70.6% | - | 91.7% | -501.1% | - | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -20.7% | - | - | - | 19.1% | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 1177.3% | - | - | - | - | 99.0% | 54.2% | 63.3% | 63.4% | 44.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2019-12-31.
Product / service
$17.40M totalThird And Fourth Targets$17.40M · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing CytomX Therapeutics against the 5 most active filers in the same SIC group.